Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

Visit IR website
Sign-up for e-mail alerts

NASDAQ: CELG	
Last Trade:	93.85
Trade Time:	4:00 PM ET Feb 20, 2018
Change:	-1.41 (1.480%)
Day Range	93.46 - 95.40
52-Week Range	88.32 - 147.17
Volume	4,820,758

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... (more)

Stock Performance

Press Releases [View all]

Feb 17, 2018
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet's Disease with Oral Ulcers

Feb 15, 2018
OTEZLA® (Apremilast) Phase II Data Showed Clinically Meaningful Improvements in Patients with Active Ulcerative Colitis

Feb 15, 2018
Celgene Corporation Elects John Weiland to Its Board of Directors

Feb 14, 2018
Celgene Announces Additional $5 Billion Share Repurchase Authorization

Feb 9, 2018
Celgene Prices $4.5 Billion of Senior Unsecured Notes

Upcoming Events [View all]

Feb 21, 2018 11:30 AM ET
RBC Capital Markets 2018 Global Healthcare Conferenc

Events [View all]

Financials [View all]

Feb 7, 2018
Annual Report (10-K)

Apr 27, 2017
Proxy Statement (DEF 14A)

Oct 26, 2017
Quarterly Report (10-Q)

Jul 27, 2017
Quarterly Report (10-Q)

Apr 27, 2017
Quarterly Report (10-Q)